Plain language summary: Sotorasib vs. docetaxel for treated KRAS G12C–mutated non–small–cell lung cancer

This Plain Language Summary of Publication article (PLSP) from Future Oncology, the CodeBreaK 200 study evaluated sotorasib for advanced non–small-cell lung cancer (NSCLC) with a KRAS G12C mutation. It compared sotorasib to docetaxel to determine which was more effective and had fewer side effects. Sotorasib is approved in over 50 countries for previously treated patients with this type of NSCLC.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS^G12C mutation: a randomised, open-label, phase 3 trial’ and was published in the Lancet.

Visit The Lancet using the link to read the original article.

• Cancer treatment
• clinical trials
• lay summary
• lung
• metastasis
• plain language summary